Tirzepatide TR
GIPR · GLP-1R dual agonist
Dual GIP and GLP-1 receptor agonist studied for incretin signalling, insulin secretion, appetite and body weight in metabolic research.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- GIPR · GLP-1R dual agonist
- Category
- Metabolic & Incretin
- Type
- Single compound
- Abbreviation
- TR
- Development and regulatory status
- Approved prescription drug (type 2 diabetes, obesity, sleep apnoea)
What researchers study
Tirzepatide is a synthetic peptide that activates both the GIP and GLP-1 receptors. Research examines how this dual incretin signalling influences insulin secretion, appetite and body weight.
Research areas
- Dual GIP and GLP-1 receptor signalling in cells
- Insulin secretion and glucose handling in animal models
- Appetite and body-weight regulation studies
- Comparative incretin pharmacology
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 3 trial
In 2,539 adults without diabetes, mean weight change at 72 weeks ranged from -15% to -20.9% across dose groups versus -3.1% with placebo
- phase 3 trial
At week 176 of longer follow-up, mean weight change ranged from -12.3% to -19.7% across dose groups versus -1.3% with placebo
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- Retatrutidetriple agonist adding glucagon-receptor activity to GIP and GLP-1 signalling
- Cagrilintideamylin analogue with a satiety pathway complementary to incretin signalling
- Eloralintideamylin receptor agonist complementary to incretin receptor signalling
